Investment Thesis
TScan Therapeutics exhibits severe profitability challenges with losses of $29.1M against minimal $982K revenue, creating an unsustainable business model losing $30 per $1 of revenue. While the strong $128.1M cash position and excellent liquidity (6.65x current ratio) provide near-term runway, the $24.3M annual operating cash burn requires either dramatic revenue acceleration or additional capital raises that would dilute shareholders. The emerging 266.7% YoY revenue growth offers potential, but current fundamentals show a company still far from sustainable operations.
Strengths
- Strong cash position of $128.1M provides 5+ years of operational runway at current burn rate
- Revenue demonstrating early commercial traction with 266.7% YoY growth trajectory
- Conservative balance sheet with Debt/Equity ratio of 0.34x and $96.9M stockholders' equity
Risks
- Severe unprofitability: -$29.1M operating loss on $982K revenue indicates fundamentally unsustainable unit economics
- Ongoing cash burn of $24.3M annually with no visibility to breakeven or profitability
- High probability of future dilutive capital raises required to sustain operations as cash reserves deplete
- Pre-commercial or very early commercial stage with no proof of sustainable revenue model
Key Metrics to Watch
- Revenue growth rate trending toward profitability threshold
- Operating cash burn rate and cash depletion timeline
- Path to and timeline for achieving gross margin positive operations
- Clinical trial progress and pipeline advancement for upcoming revenue drivers
Financial Metrics
Revenue
982.0K
Net Income
-28.7M
EPS (Diluted)
$-0.22
Free Cash Flow
-24.3M
Total Assets
202.0M
Cash
128.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,967.3%
Net Margin
-2,919.1%
ROE
-29.6%
ROA
-14.2%
FCF Margin
-2,479.5%
Balance Sheet & Liquidity
Current Ratio
6.65x
Quick Ratio
6.65x
Debt/Equity
0.34x
Debt/Assets
52.0%
Interest Coverage
-42.29x
Long-term Debt
32.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:45:34.507161 |
Data as of: 2026-03-31 |
Powered by Claude AI